Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
Research ArticleResearch

Are patients with hyperlipidemia undertreated?

Study of patients admitted to hospital with coronary events

Alan H. Lipson, Wendy M. Fallis, Xiqui Wang and Yanqing Yi
Canadian Family Physician September 2007, 53 (9) 1502-1507;
Alan H. Lipson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: alipson@vgh.mb.ca
Wendy M. Fallis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiqui Wang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yanqing Yi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF
Loading

Large-scale clinical trials have demonstrated that reducing serum low-density lipoprotein cholesterol (LDL-C) is associated with a lower incidence of coronary events1–5 in both primary3,4,6 and secondary1,2,5 prevention situations. Virtually all trials demonstrated a decrease in coronary death and nonfatal myocardial infarction (MI), and some showed reductions in total mortality.1,2,5 Other studies have found that aggressive lipid lowering reduces the number of ischemic events at about the same rate as coronary angioplasty does.7

Such findings have had a central role in formulating guidelines for treating dyslipidemias. The Canadian guidelines in use as we initiated this study were published in 2000.8 In these guidelines, target LDL–C levels for patients deemed to be at low, moderate, high, or very high risk (as defined by their 10-year risk of coronary artery disease) were set at <5.0, <4.0, <3.0, and <2.5 mmol/L, respectively.

Based on Framingham data, risk-assessment tools have been developed to aid clinicians in assessing patients’ risk for having cardiac events so that therapy can be tailored to risk status.8,9 Evidence suggests, however, that many patients are undertreated and are not achieving guideline-recommended target lipid levels.10,11 In this study, we set out to quantify this phenomenon in our community by means of a retrospective chart review of patients admitted to hospital with certain cardiovascular events.

METHOD

We conducted the study at an acute care community hospital in Winnipeg, Man. Before we started the study, we obtained approvals from the University of Manitoba Health Research Ethics Board and from the hospital. The Research Ethics Board waived the need for patient consent to access medical charts. We reviewed consecutive charts with admission diagnoses of acute MI, unstable angina, or acute coronary syndrome from the 2002–2003 and 2003–2004 fiscal years. Charts were excluded if lipid levels had not been measured within 24 hours of admission, if there was inadequate history to establish risk status, if patients were not expected to survive for 1 year due to noncardiac illness, or if patients were treated with only palliative measures.

We used a “treat to target” assessment tool for calculating the 10-year risk of coronary artery disease in nondiabetic people, as recommended by the Canadian Working Group on Hypercholesterolemia and Other Dyslipidemias.8 Depending on the person’s risk category, the tool directs users to the recommended target levels for LDL-C. We considered patients with diabetes as very high risk in keeping with the Canadian guidelines and based on the observation that diabetic patients without overt vascular disease appear to share the same risk as nondiabetic patients with documented vascular disease.12

Using a moderate effect size of 0.6 standard deviations1,5,13 and an α set at .05 (1-tailed), power analysis revealed that we needed a sample size of 26 subjects per risk group (low, moderate, high, and very high) to achieve a power of 90%14 in detecting a significant difference between actual and target LDL-C levels.

Pertinent demographic information was recorded along with the information necessary to complete a “treat to target” tool based on Framingham risk calculations. Each subject’s risk points were added together to determine their 10-year risk of having coronary artery disease, allowing for risk categorization. Target LDL-C levels were recorded for each subject based on the 2000 Canadian guidelines.8

Our initial intent was to review charts until we had adequate data for analysis in each risk category. It became apparent, however, that very few patients fell into the high-risk category, and further culling of charts to locate sufficient patients in that category would have exceeded our resources. Hence, the 3 records in the high-risk group were not subjected to further analysis. Data were entered into an Excel 5.0 spreadsheet and analyzed using the Statistical Analysis software (SAS Institute).

Descriptive statistics were used to report numerical data on age, total cholesterol, high-density lipoprotein cholesterol, LDL-C, blood pressure (BP), calculated risk, and length of stay in hospital. Categorical data, such as primary diagnosis, smoking status, diabetes, and outcome, were described by relative frequencies expressed in percentages. Relative frequencies of risk categories and use of lipid-lowering agents before admission were calculated. One-sample t tests were used to determine the difference between actual and target LDL-C levels in each risk category. A 1-tailed α of .05 was used to determine statistical significance.

RESULTS

A total of 153 patient records were included in the analysis. Baseline characteristics and primary diagnoses are shown in Table 1. Results of risk stratification and LDL-C level findings stratified by risk category are shown in Table 2. Of the 153 patients evaluated, 21.6% were determined to be at low risk, 15.7% at moderate risk, and 60.8% at very high risk of coronary events. Mean LDL-C levels for the low- and moderate-risk groups were significantly lower than guideline target levels (P < .001, respectively). For the very high-risk group, however, although the mean LDL-C level was just above the target level (P = .1), nearly half the subjects (48.4%) had LDL-C levels above the recommended target level (Table 3).

View this table:
  • View inline
  • View popup
Table 1 Patient and characteristics (N = 153)

A) Mean characteristics and laboratory values; B) Baseline conditions, primary diagnoses, and outcomes.

View this table:
  • View inline
  • View popup
Table 2

Risk categories and low-density lipoprotein cholesterol (LDL-C) levels: N = 153.

View this table:
  • View inline
  • View popup
Table 3

Low-density lipoprotein cholesterol levels over target among very high-risk patients: N = 45.

Lipid-lowering agents had been prescribed to 24.8% of patients before admission. Percentages of patients prescribed lipid-lowering agents in each risk category are shown in Table 2. The mean LDL-C level for patients prescribed lipid-lowering agents (2.34 ± 0.80) was significantly lower than that of patients not receiving these agents (2.86 ± 0.88, P = .002). Use of lipid-lowering agents in very high-risk patients was also significantly associated with achieving target LDL-C levels. Among the very high-risk patients taking lipid-lowering agents, 62.5% achieved target LDL-C levels, while among those not taking these agents, only 45.9% had LDL-C levels in the target range (P < .03). Significantly more patients in the very high-risk group were taking lipid-lowering agents compared with patients in the low- or moderate-risk groups (P = .012, respectively). The mean LDL-C level in the very high-risk group was significantly lower than the mean LDL-C levels in the low-risk (P < .01) and moderate-risk (P < .04) groups.

The distribution of LDL-C levels of very high-risk patients whose levels were above target is shown in Table 3. Nearly half the patients (45/93, 48.4%) stratified into the very high-risk category had LDL-C levels above the target level of <2.5 mmol/L. Among the 7 people who died, 5 were in the very high-risk category.

DISCUSSION

Most of the patients presenting to our hospital with acute MI, acute coronary syndrome, or unstable angina were in the very high-risk category for coronary events. Almost half of them had LDL-C levels above the recommended level. Although more patients in this group were taking lipid-lowering agents than lower-risk patients were, two thirds of them (65.6%) were not taking them at all. Even among very high-risk patients taking lipid-lowering agents, 37.5% had LDL-C levels above target.

Unfortunately, these results demonstrate no improvement over levels published in earlier studies.15,16 The Lipid Treatment Assessment Project15 found that 63% of high-risk patients and 82% of patients with coronary artery disease (very high risk) failed to reach their target lipid levels. The Third National Health and Nutrition Examination Survey16 found that, among survivors of MI or stroke with known hypercholesterolemia, 46% had poorly controlled lipid levels.

A 2003 Canadian survey of management of dyslipidemia in an academic family medicine clinic10 identified a cohort of patients for whom target LDL-C levels were believed to be <2.5. Only 44% of patients with diabetes mellitus or documented coronary artery disease were prescribed lipid-lowering treatment, and only 48% achieved target LDL-C levels. In our survey, the proportion of very high-risk patients who attained target LDL-C levels was very similar (51.6%). Even fewer of our very high-risk patients (34.4%) were prescribed lipid-lowering treatment. Although the mean LDL-C level in very high-risk patients in our study was close to the target, almost half the patients’ levels were higher than target: 26 patients (58%) had LDL-C levels at least 25% above target, and 9 (20%) had levels at least 50% above target. Most practitioners would consider these differences clinically significant in a very high-risk group.

Our data indicate that, despite their failure to achieve target LDL-C levels, very high-risk patients in the community were treated more aggressively than other patients were. The mean LDL-C level of patients in the very high-risk group was significantly lower than levels in the moderate- or low-risk groups (2.53 vs 2.98 and 3.01, respectively). In addition, 34.4% of very high-risk patients were taking lipid-lowering agents at the time of presentation, more than double the frequency in the other groups (9.1% in the low-risk category and 12.5% in the moderate-risk category), a statistically significant difference.

Many factors could be responsible for LDL-C levels being above target and for the low proportion of very high-risk patients taking lipid-lowering agents. Physicians might not know enough about or be in disagreement with guidelines, or they might not be motivated enough to follow the guidelines. Patient and environmental factors could include noncompliance, denial, concern regarding side effects, suspicion regarding risk-benefit ratios, use of herbal remedies, and cost. We did not explore these factors or determine their relative contributions.

Limitations

This study was a retrospective chart review in a hospital. Office records, including patients’ lipid levels and the duration of lipid-lowering therapy were generally unavailable. Framingham-based risk assessment, although recommended by guidelines, is neither the only nor necessarily the best predictor of risk. Some risk factors, such as family history, were not taken into account.

Blood pressure at time of presentation to hospital might not represent “usual” BP. We attempted to correct this by using the first documented daytime BP on the second day of admission when patients were free of pain. Given patients’ recent physical stress and emotional reactions, their BP might still have been higher than usual. On the other hand, many patients would have received new or increased doses of BP-lowering medications and would have been on bed rest, which might have led to underestimation of true BP. Most patients still fell into the very high-risk category, suggesting that the effect of any underestimation of BP on our results was negligible.

With the exception of the high-risk group, the sample size was adequate to determine statistical significance. We cannot comment further on the high-risk group, but this has no effect on the validity of our findings concerning the other groups. There were only 24 patients in the moderate-risk group when we stopped collecting data, but the difference between their mean LDL-C level and the target level was highly statistically significant; finding 2 more such patients would have taxed our resources with no chance of having a material effect on this finding.

Patients in previously published surveys7,15 have been identified from pools of stable outpatients. Our study adds to the current literature by identifying patients at a different point in the spectrum of hyperlipidemia and coronary artery disease: on admission to hospital with coronary events, at which time we were able to estimate their risk of such events.

Conclusion

Failure to achieve target lipid levels represents a possible missed opportunity to prevent coronary events and hospital admissions. Our results clearly mirror the results of other surveys10,11,15,17 and suggest that patients in our community were undertreated with respect to reaching LDL-C target levels. Our findings indicate an opportunity to prevent patient morbidity and hospitalizations related to vascular events by influencing both physicians and patients. While new Canadian guidelines were published in late 2003,18 and more recently in 200619 (recommending more aggressive lipid lowering), our study offers a unique glimpse into the “state of affairs” of treating hyperlipidemia at the end of the 2000 guidelines’ lifespan. These findings also suggest that we have much work to do to conform to current recommendations.

Notes

EDITOR’S KEY POINTS

  • Despite large-scale trials demonstrating that reductions in low-density lipoprotein cholesterol (LDL-C) levels are associated with a lower incidence of coronary events, evidence indicates that many patients are undertreated and are not achieving guideline-recommended target lipid levels.

  • This study sought to quantify this phenomenon using a retrospective chart review of patients admitted to an acute care community hospital with certain cardiovascular events.

  • Nearly half the patients stratified into the very high-risk group had LDL-C levels above the recommended target.

POINTS DE REPÈRE DU RÉDACTEUR

  • Malgré les études à grande échelle démontrant que la réduction du cholestérol des lipoprotéines de faible densité (LDL-C) est associée à une réduction des incidents coronariens, les données actuelles suggèrent que plusieurs patients sont soustraités et n’atteignent pas les niveau cibles recommandés par les directives de pratique.

  • Cette étude voulait quantifier ce phénomène par une revue rétrospective de dossiers de patients admis pour certains problèmes cardiovasculaires à un hôpital communautaire de soins actifs.

  • Près de la moitié des patients du groupe à risque très élevé avaient des niveaux de LDL-C dépassant les cibles recommandées.

Footnotes

  • This article has been peer reviewed.

  • Contributors

    Dr Lipson conceived and designed the study and wrote this paper. Dr Fallis refined the study design, supervised the collection of data, and contributed to writing this paper. Drs Lipson and Fallis take responsibility for the integrity of the paper as a whole. Dr Wang was involved in study design and was responsible for the power calculations and determination of sample sizes. He also supervised Ms Yi and contributed to writing this paper. Ms Yi did most of the data analysis.

  • Competing interests

    None declared

  • Copyright© the College of Family Physicians of Canada

References

  1. ↵
    Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Sacks FM,
    2. Pfeffer MA,
    3. Moye LA,
    4. Rouleau JL,
    5. Rutherford JD,
    6. Cole TG,
    7. et al
    . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Sever PS,
    2. Dahlöf B,
    3. Poulter NR,
    4. Wedel H,
    5. Beevers G,
    6. Caulfield M,
    7. et al
    . Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Downs JR,
    2. Clearfield M,
    3. Weis S,
    4. Whitney E,
    5. Shapiro DR,
    6. Beere PA,
    7. et al
    . Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
    OpenUrlCrossRefPubMed
  5. ↵
    The Long Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Shepherd J,
    2. Cobbe SM,
    3. Ford I,
    4. Isles CG,
    5. Lorimer AR,
    6. MacFarlane PW,
    7. et al
    . Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Pitt B,
    2. Waters D,
    3. Brown WV,
    4. van Boven AJ,
    5. Schwartz L,
    6. Title LM,
    7. et al
    . Atorvastatin Versus Revascularization Treatment Investigators. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999;341:70-6.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Fodor JG,
    2. Frohlich JJ,
    3. Genest JJ,
    4. McPherson PR
    . Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. CMAJ 2000;162:1441-7.
    OpenUrlFREE Full Text
  9. ↵
    1. Lambert AP,
    2. Hunt MA,
    3. Day AP,
    4. Bayly GR,
    5. Dayan CM
    . Reproducibility of individualized coronary heart disease risk calculations in patients with diabetes mellitus. Diabet Med 2002;19:514-7.
    OpenUrlPubMed
  10. ↵
    1. Alzahrani T,
    2. Marrat S,
    3. Haider A
    . Management of dyslipidemia in primary care. Can J Cardiol 2003;19:1499-502.
    OpenUrlPubMed
  11. ↵
    1. Majumdar SR,
    2. Gurwitz JH,
    3. Soumerai SB
    . Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med 1999;14:711-7.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Haffner S,
    2. Lehto S,
    3. Rönnemaa T,
    4. Pyörälä K,
    5. Laakso M
    . Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Teo KK,
    2. Burton JR,
    3. Buller CE,
    4. Plante S,
    5. Catellier D,
    6. Tymchak W,
    7. et al
    . Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 2000;102:1748-54.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Machin D,
    2. Campbell MJ,
    3. Fayers PM,
    4. Pinol AP
    . Sample size tables for clinical studies. London, Engl: Blackwell Science; 1997.
  15. ↵
    1. Pearson TA,
    2. Laurora I,
    3. Chu H,
    4. Kafonek S
    . The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Qureshi AI,
    2. Suri MF,
    3. Guterman LR,
    4. Hopkins LN
    . Ineffective secondary prevention in survivors of cardiovascular events in the US population: report from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2001;161:1621-8.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Schectman G,
    2. Hiatt J
    . Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Med 1996;100:197-204.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Genest J,
    2. Frohlich J,
    3. Fodor G,
    4. McPherson R
    ; Working Group on Hypercholesterolemia and Other Dyslipidemias. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ 2003;169:921-4.
    OpenUrlFREE Full Text
  19. ↵
    1. McPherson R,
    2. Frohlich J,
    3. Fodor G,
    4. Genest J
    ; Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006;22:913-7.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Family Physician: 53 (9)
Canadian Family Physician
Vol. 53, Issue 9
1 Sep 2007
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Are patients with hyperlipidemia undertreated?
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Are patients with hyperlipidemia undertreated?
Alan H. Lipson, Wendy M. Fallis, Xiqui Wang, Yanqing Yi
Canadian Family Physician Sep 2007, 53 (9) 1502-1507;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Are patients with hyperlipidemia undertreated?
Alan H. Lipson, Wendy M. Fallis, Xiqui Wang, Yanqing Yi
Canadian Family Physician Sep 2007, 53 (9) 1502-1507;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • METHOD
    • RESULTS
    • DISCUSSION
    • Limitations
    • Conclusion
    • Notes
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Patients eligible and referred for bariatric surgery in southeastern Ontario
  • PEER systematic review of randomized controlled trials
  • Electronic communication between family physicians and patients
Show more Research

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2021 by The College of Family Physicians of Canada

Powered by HighWire